This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PPI-2458

GlaxoSmithKline plc

Drug Names(s): PPI-2458

Description: PPI-2458 is a novel, proprietary molecule that acts by irreversibly inhibiting the enzyme methionine aminopeptidase type 2, or MetAP2. PPI-2458 is based on the fumagillin class of compounds. This class of compounds has been shown to prevent both abnormal cell growth and the formation of new blood vessels, which contribute to the growth of aberrant tissues in diseases such as cancer and rheumatoid arthritis.

Deal Structure: PPI-2458 was developed by Praecis Pharmaceuticals until the company was aquired by GlaxoSmithKline in February 2007.


PPI-2458 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug